Clinical Trial: Study of Trastuzumab Deruxtecan in Combination With Pembrolizumab Versus Pembrolizumab With Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT06899126) titled 'Study of Trastuzumab Deruxtecan in Combination With Pembrolizumab Versus Pembrolizumab With Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer' on March 21.

Brief Summary: This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu(R)) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic non-squamous NSCLC, whose tumors have HER2-overexpressing and PD-L1 TPS <50% without known AGA that have locally available thera...